TMToshinori Matsushige

Toshinori Matsushige

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Toshinori Matsushige has a total of 156 co-authors. Here are the top co-authors by number of shared publications:

  • Kaoru Kurisu

    Hiroshima City Asa Citizens Hosp, Dept Neurosurg & Intervent Neuroradiol, Asakita Ku, 2-1-1 Kabeminami, Hiroshima 7310293, Japan

    19 shared publications
  • Shigeyuki Sakamoto

    Department of Neurosurgery, Itsukaichi Memorial Hospital, Itsukaichi 731-5156, Japan

    18 shared publications
  • Chiaki Ono

    Department of Radiology, Hiroshima City North Medical Center Asa Citizens Hospital

    13 shared publications
  • Masahiro Hosogai

    Department of Neurosurgery and Interventional Neuroradiology, Hiroshima City North Medical Center Asa Citizens Hospital, Hiroshima, Japan

    12 shared publications
  • Yukishige Hashimoto

    Department of Neurosurgery and Interventional Neuroradiology, Hiroshima City North Medical Center Asa Citizens Hospital

    12 shared publications
  • Hiroki Takahashi

    Department of Neurosurgery and Interventional Neuroradiology, Hiroshima City North Medical Center Asa Citizens Hospital

    11 shared publications

Latest Publications

  • Open Access

    Correction: Kondo et al. Multicenter Validation of a Unified Evidence-Based Treatment Protocol Focusing on Clazosentan for Managing Subarachnoid Hemorrhage. J. Clin. Med. 2025, 14, 3423

    by Hiroshi Kondo, Daizo Ishii, Masashi Kuwabara, Takeshi Hara, Kaoru Kurisu, Masayuki Sumida, Fusao Ikawa, Shinji Ohba, Atsushi Tominaga, Naohiko Obayashi, et al.

  • The beneficial effects of clazosentan on the perioperative management of patients with subarachnoid hemorrhage

    by Shinichiro Oku, Toshinori Matsushige, Yuichiro Takemoto, Masahiro Hosogai, Yasutaka Akino, Nobutaka Horie

    Objective clazosentan has been approved in Japan for the prevention of cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage (aSAH) and has contributed to the significant suppression of angiographic vasospasm in clinical practice. We herein report the beneficial effects of clazosentan on the perioperative management of patients with aSAH. Methods The study population comprised 102 consecutive patients with aSAH: 49 received conventional treatment (fasudil with triple-H therapy) before May 2022, and 53 were treated with the current protocol (clazosentan management) thereafter. The factors associated with vasospasm and perioperative management, as well as the implementation status of postoperative rehabilitation, hospitalization and outcomes at discharge were compared. Results the prevalence of angiographic vasospasm was significantly lower in the clazosentan group than in the fasudil group (32.1% vs. 59.2%, p < 0.01). Although the incidence of vasospasm-related DCI and favorable outcomes at discharge tended to be better in the clazosentan group, these differences were not statistically significant. Despite equivalent timing of rehabilitation initiation, sitting training and physiotherapy in the training room were initiated significantly earlier in the clazosentan group than in the fasudil group (6.5 days vs. 10.7 days, p < 0.01; 11.8 days vs. 16.1 days, p < 0.01). Furthermore, the length of hospital stay was significantly shorter in the clazosentan group than in the fasudil group (22.3 days vs. 29.6 days, p < 0.01). Conclusion clazosentan-based management was associated with reduced angiographic vasospasm, earlier rehabilitation, and shorter hospitalization compared with fasudil-based management.

  • Open Access

    Safety and Efficacy of Direct Oral Anticoagulants for Venous Thromboembolism in the Acute Phase of Cerebral Hemorrhage

    by Masashi Niimi, Toshinori Matsushige, Masahiro Hosogai, Hiroki Takahashi, Shinichiro Oku, Nobutaka Horie

    【背景および目的】脳出血急性期における静脈血栓塞栓症(venous thromboembolism: VTE)に対する抗凝固療法はいまだ一定の見解がない.今回我々はVTEと診断した患者に対するDOAC投与の安全性と有用性を検討した.【方法】2022年10月から2024年9月に,1週間以上入院した脳出血患者連続191例を対象とした.重症度に応じて1週間に1回以上D-dimer値を測定した.VTE発症に関連する因子およびVTE患者に対するDOAC投与の安全性と有用性を統計学的に評価した.【結果】VTEの危険因子は入院中D-dimer最大値(p=0.04),入院時Glasgow Coma Scale(GCS)(p=0.03)であった.VTEは14例(7.3%)で認められ,全例とも無症候性であった.DOAC投与開始後平均6.5日でD-dimer値は正常化した.脳出血の増大や全身の出血性合併症は認めなかった.【結論】脳出血急性期におけるD-dimer値の測定を行うことで,VTEの早期診断が可能であった.概ね発症後7日程度で一度D-dimer値の測定が考慮される.DOACを用いた抗凝固療法は出血性合併症なくVTEの症候化を予防できる可能性がある.

  • Open Access

    Chronological Changes in Intra-aneurysmal Signal Intensity on T1-weighted Black Blood Images after Endovascular Treatment for Unruptured Intracranial Aneurysms

    by Yukishige Hashimoto, Toshinori Matsushige, Reo Kawano, Masahiro Hosogai, Hiroki Takahashi, Shinichiro Oku, Mayumi Kaneko, Chiaki Ono, Nobutaka Horie

    Intra-aneurysmal thrombus formation is crucial for the healing of endovascularly treated aneurysms. This study evaluated whether T1-weighted black blood imaging can monitor thrombus formation by examining the relationship between chronological signal intensity changes and aneurysm occlusion status after flow diverter stenting and coil embolization. We retrospectively analyzed 78 patients with 83 aneurysms (flow diverter stenting: 28, coil embolization: 55) who underwent T1-weighted black blood imaging at 1 week, 3 months, and 6 months post-treatment. Relative signal intensity was calculated as the signal intensity of the aneurysmal sac divided by the signal intensity of the genu of the corpus callosum. Satisfactory occlusion (O'Kelly-Marotta grades C or D) at 6 months was the primary endpoint for flow diverter stenting, while residual intra-aneurysmal blood flow during the follow-up was defined as recurrence after coil embolization. In flow diverter stenting cases, relative signal intensity was elevated at 3 months and remained stable. Relative signal intensity 3 months after flow diverter stenting was significantly higher in the satisfactory occlusion group than the non-satisfactory occlusion group (0.99 ± 0.55 vs. 0.51 ± 0.34, p = 0.03) and independently associated with satisfactory occlusion (adjusted odds ratio per 0.1 increase = 1.35, p = 0.01). In coil embolization cases, relative signal intensity was highest at 1 week and decreased linearly. Higher relative signal intensity 1 week after coil embolization was associated with lower recurrence rates (0.60 ± 0.22 vs. 0.41 ± 0.12, p = 0.002) and independently linked to aneurysm recurrence (adjusted odds ratio per 0.1 increase = 0.55, p = 0.004). Relative signal intensity changes on T1-weighted black blood imaging differ between flow diverter stenting and coil embolization. High relative signal intensity 3 months after flow diverter stenting and relative signal intensity 1 week after coil embolization were significantly correlated with favorable outcomes.

  • Appearance and Disappearance of Intracranial Aneurysm Wall Enhancement during Follow-Up: A Multicenter Cohort Study

    by Laura T. van der Kamp, Irene C. van der Schaaf, Myriam Edjlali, Olivier Naggara, Toshinori Matsushige, Diederik O. Bulters, Ronneil Digpal, Chengcheng Zhu, David Saloner, Peng Hu, et al.

    BACKGROUND AND PURPOSE: Aneurysm wall enhancement on MRI after administration of gadolinium is associated with aneurysm growth or rupture. Aneurysm wall enhancement has mostly been studied at baseline. The change in the presence or absence of aneurysm wall enhancement with time is largely unknown but can provide a better understanding of the pathophysiological processes occurring within the aneurysm wall. Therefore, we aimed to determine the proportion of aneurysm wall enhancement appearance or disappearance. MATERIALS AND METHODS: In this multicenter cohort study, we analyzed individual patient data from 11 international cohorts. Patients 18 years of age or older with at least 1 untreated saccular unruptured intracranial aneurysm were included if they had 2 consecutive MRIs with aneurysm wall imaging. A Wilson score interval was used to calculate confidence intervals for the proportion of aneurysms with aneurysm wall enhancement changes, defined as appearance or disappearance between the 2 MRIs. RESULTS: We included 305 patients with 387 unruptured intracranial aneurysms. Aneurysm wall enhancement was present at baseline in 142 (37%) aneurysms in 122 patients. Aneurysm wall enhancement appeared or disappeared in 20/387 aneurysms (5.2% [95% CI, 3.4–7.8]) after a median follow-up of 12 months (interquartile range, 5–13). Of the 245 aneurysms without enhancement at baseline, 13 (5.3% [95% CI, 3.1–8.9]) had the appearance of wall enhancement at the second MR aneurysm wall imaging. Of the 142 aneurysms with aneurysm wall enhancement at baseline, 7 aneurysms (4.9% [95% CI, 2.4–9.8]) had the disappearance of aneurysm wall enhancement. CONCLUSIONS: Most unruptured intracranial aneurysms have persistent presence or absence of aneurysm wall enhancement during a median 1-year follow-up period. This finding suggests that underlying pathophysiological processes in the aneurysm wall are long-lasting. Graphical Abstract


  • Open Access

    Technical Feasibility and Efficacy of Flow-Guided Microcatheter Delivery of i-ED Coils for Parent Artery Occlusion in Posterior Fossa Peripheral Aneurysms

    by Hiroki Takahashi, Toshinori Matsushige, Masahiro Hosogai, Shinichiro Oku, Nobutaka Horie

    Peripheral aneurysms in the posterior circulation are rare vascular pathologies and their treatment remains challenging. Microsurgical procedures for these aneurysms are complex, lengthy, and highly invasive. Endovascular parent artery occlusion could be considered as an alternative treatment of choice; however, it is inherently challenging due to the small vessel caliber and fine manipulation required. Small bore flow-guided microcatheters (1.5 Fr) with high peripheral accessibility are currently available, whereas compatible coils remain limited. The brand-new i-ED coils can be compatible with these microcatheters. We herein present our patient series of peripheral aneurysms in the posterior fossa that were treated endovascularly, and discuss key technical tips and potential pitfalls.


  • Open Access

    Apolipoprotein A1 Levels Are Inversely Associated with Aneurysm Wall Enhancement in Unruptured Intracranial Aneurysms

    by Masahiro Hosogai, Toshinori Matsushige, Saya Tsuchigauchi, Hiroki Takahashi, Shinichiro Oku, Nobutaka Horie

    Current magnetic resonance vessel wall imaging enables the detection of atherosclerotic changes in the walls of intracranial aneurysms. Lipid accumulation in the intracranial aneurysm wall is involved in aneurysm neovascularization and chronic inflammation and may lead to aneurysm enlargement and rupture. Therefore, in the present study, we examined the relationship between atherosclerotic changes identified by vessel wall imaging and systemic atherosclerosis-related risk factors. A total of 111 patients with 156 unruptured intracranial aneurysms who underwent magnetic resonance vessel wall imaging and atherosclerotic protein examinations between April 2021 and November 2023 were reviewed. Data on atherosclerotic proteins were obtained from peripheral blood samples. The relationships between aneurysm wall enhancement and patient demographic data, aneurysm morphology, and atherosclerosis-related risk factors were assessed. Fifty-seven of 156 unruptured intracranial aneurysms (36.5%) showed aneurysm wall enhancement. In a univariate logistic regression analysis, age (p = 0.007), male sex (p = 0.023), morphological factors such as maximum diameter (p < 0.001) and irregular shape (p < 0.001), and the levels of apolipoprotein A1 (<0.001) and apolipoprotein B/apolipoprotein A1 (0.004) correlated with aneurysm wall enhancement. In the multivariate logistic regression analysis, age (odds ratio: 1.05, 95% confidence interval: 1.02-1.10), male sex (odds ratio: 3.83, 95% confidence interval: 1.46-10.01), maximum diameter (odds ratio: 1.19, 95% confidence interval: 1.01-1.45), irregular shape (odds ratio: 5.01, 95% confidence interval: 2.10-12.73), and apolipoprotein A1 levels (odds ratio: 0.97, 95% confidence interval: 0.94-0.99) correlated with aneurysm wall enhancement. Low levels of apolipoprotein A1, which may function as an atherosclerotic protein, were associated with specific aneurysm wall features in vessel wall imaging. In future studies, these results will contribute to the identification of factors that promote the destabilization of unruptured intracranial aneurysms.


  • Open Access

    Multicenter Validation of a Unified Evidence-Based Treatment Protocol Focusing on Clazosentan for Managing Subarachnoid Hemorrhage

    by Hiroshi Kondo, Daizo Ishii, Masashi Kuwabara, Takeshi Hara, Kaoru Kurisu, Masayuki Sumida, Fusao Ikawa, Shinji Ohba, Atsushi Tominaga, Naohiko Obayashi, et al.

    Background/Objectives: Effective management of aneurysmal subarachnoid hemorrhage (aSAH) requires an evidence-based treatment protocol. This study examines the outcomes of a unified, multicenter protocol emphasizing postoperative clazosentan as the first-line treatment for vasospasm. Methods: A standardized protocol prioritizing systemic management with clazosentan for vasospasm was implemented in April 2023. Cases treated between April 2022 and March 2024 were categorized into four groups: preprotocol fasudil treatment (PrF), preprotocol clazosentan treatment (PrC), postprotocol fasudil treatment (PoF), and postprotocol clazosentan treatment (PoC); these groups were analyzed. Results: Among 407 registered cases, 322 were eligible for analysis (PrF, 128; PrC, 69; PoF, 28; PoC, 97). PoC exhibited significantly lower angiographic vasospasm rates and had a lower incidence of symptomatic vasospasm compared with PrF (p = 0.048, p = 0.057). Logistic regression identified the clazosentan protocol as a predictive factor for vasospasm reduction (p = 0.02, OR 0.46 [0.22–0.94]; p = 0.022, OR 0.38 [0.16–0.91]). PoC experienced less fluid retention than the PrC (p < 0.001). Logistic regression confirmed protocol adherence with protocol reduced complications (p < 0.001, OR 0.24 [0.11–0.52]), included fluid retention (p < 0.001, OR 0.088 [0.03–0.29]). In older patients, no significant differences in vasospasm or complications were observed between PrF and PoC, but a trend toward reduced complications was observed in World Federation of Neurosurgical Societies (WFNS) grade V cases. Conclusions: Clazosentan-first protocol effectively reduces vasospasm and complications in aSAH management. It is also safe for older patients and those with WFNS grade V, offering a promising treatment strategy.


  • Open Access

    Potential of low apolipoprotein A-I as a surrogate marker of vulnerable carotid artery plaques

    by Saya Tsuchigauchi, Toshinori Matsushige, Yukishige Hashimoto, Masahiro Hosogai, Hiroki Takahashi, Shohei Kobayashi, Takeo Shishido, Naoyuki Hara, Kenta Kaneyoshi, Shota Uchida, et al.


  • Open Access

    Efficacy and safety of the contralateral approach to vascular lesions in the vertebral artery: patient series

    by Hiroki Takahashi, Toshinori Matsushige, Masahiro Hosogai, Shinichiro Oku, Nobutaka Horie

    BACKGROUND: Endovascular treatment is preferred over microsurgical clipping for intracranial aneurysms in the posterior circulation. However, access to lesions, particularly those in the regions of the vertebral artery (VA) and the posterior inferior cerebellar artery (PICA), is technically challenging in terms of the vessel diameter of the ipsilateral VA or the branching angle of the PICA. OBSERVATIONS: Nine cases of intracranial aneurysms in the region of the PICA, which were endovascularly treated with an approach beyond the vertebrobasilar junction (VBJ) from the contralateral VA in the last 4 years, are described herein. All procedures, namely stent deployment, the use of a balloon catheter, and coiling, were safely performed using the contralateral approach. Neither rebleeding nor ischemic complications occurred. All patients had favorable outcomes and no recurrence. LESSONS: All aneurysms were successfully treated using an adjunctive technique with an additional approach beyond the VBJ from the contralateral VA. The combination of both ipsilateral and contralateral approaches to VA-PICA or PICA lesions contributes to safe and effective endovascular treatment. https://thejns.org/doi/10.3171/CASE24420